Humana In Vivo Reprogramming in Regenerative Medicine (Stem Cell Biology and Regenerative Medicine)

This new volume reviews current progress on different approaches of in vivo reprogramming technology. Leaders in the field discuss how in vivo cell lineage reprogramming can be used for tissue repair and regeneration in different organs, including brain, spinal cord, pancreas, liver and heart. Recent studies on in vivo cell reprogramming towards pluripotency are reviewed; examples are given to show its potential in regenerative medicine. In each chapter, the regenerative potential of different in vivo reprogramming approaches is discussed in detail. More specifically, how different tissue failures or damages can be treated with this technology is explained. Examples from various animal models are given and the regenerative potential of in vivo reprogramming is compared to that of cell transplantation studies. The last chapter discusses current challenges of these preclinical studies and gives suggestions in order to improve the current strategies. Future directions are indicated for the transition of in vivo reprogramming technology to clinical settings. This is among the first books in the literature which specifically focuses on the in vivo reprogramming technology in regenerative medicine and these chapters collectively cover one of the most important and exciting topics of regenerative medicine. From the Back Cover There have been significant improvements in the development of cell based therapies; however, current treatment strategies still suffer from some problems: the need for long in vitro culture conditions, inefficient delivery of cells by scaffolds and low incorporation and grafting efficiencies. Therefore, in vivo reprogramming has emerged as a novel treatment technology. In the process of in vivo reprogramming, cells switch to another cell type within the living organism. Leaders in the field discuss how in vivo reprogramming can be used for tissue repair and regeneration in different organs, including pancreas, liver and heart. Furthermore, recent studies on in vivo cell reprogramming towards pluripotency are also reviewed. Current challenges of these preclinical studies are discussed and hypothesis and suggestions are given in order to improve the current strategies to achieve translation into clinic.  About the Author Dr. Açelya Yilmazer is as an assistant professor at the Biomedical Engineering Department and the vice director of the Stem Cell Institute of Ankara University. After receiving a BSc in Biology from the Middle East Technical University, she completed her MSc degree in Cancer Immunotherapy at the University of Nottingham and obtained her PhD in the Nanomedicine Lab based in the School of Pharmacy, University College London. She has been selected as the Best Young Investigator in Turkey by the Turkish Society of Medical Biology and Genetics. Her research laboratory focuses on cell reprogramming technologies and development of novel nanomaterial systems for directing cell fate. She is a member of the International Society of Stem Cell Research and the Biomaterials and Tissue Engineering Society of Turkey.